Article thumbnail

Cytokine Reduction in the Treatment of Joint Conditions

By J. D. Sipe, J. Martel-Pelletier, I. G. Otterness and J.-P. Pelletier

Abstract

The destruction of joints caused by rheumatoid arthritis and osteoarthritis is characterized by an imbalance of enzyme catalysed cartilage breakdown and regeneration. A complex cytokine network perpetuates joint conditions by direct regulation of metalloproteases, by indirect recruitment of cells that secrete degradative enzymes, and by inhibition of reparative processes. The destructive action of cytokines such as interleukin-1, interleukin-6 and tumour necrosis factor-α can be modulated at multiple points associated either with cytokine production or with cytokine action. Potential agents for cytokine reduction include selective anti-cytokine antibodies, anticytokine receptor antibodies, cytokine receptor antagonist proteins, and soluble and chimeric cytokine receptor molecules. Pharmacologic regulation of IL-1 and TNFα remain primary targets for treatment of arthritis, and results of early clinical trials are promising. However, the results of long-term clinical trials will be required to support the value of anti-cytokine therapy in treatment of arthritis

Topics: Research Article
Publisher: Hindawi Publishing Corporation
OAI identifier: oai:pubmedcentral.nih.gov:2367051
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (1993). A possible systemic component of osteoarthritis (OA): elevated concentrations (by ELISA) of C-reactive protein (CRP) in ofOA patients and modulation by tenidap. ArthritisRheum
  2. (1993). A preformed ribozyme destroys cytokine mRNA in human cells. Arthritis Rheum
  3. (1990). A receptor for tumor necrosis factor defines unusual family of cellular and viral proteins. Science
  4. (1990). A secretable cell surface mutant of tumor necrosis factor (TNF) kills by cell-to-cell contact. Cell
  5. (1989). A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity. JBiol Chem
  6. (1990). Adhesion receptors of the immune system.
  7. (1975). An endotoxininduced factor that necrosis of tumors.
  8. (1994). An ultrasensitive chemiluminoenzymatic assay for the quantification of human tissue kininogen.
  9. (1990). Analysis of ILl and TNF alpha gene expression in human rheumatoid synoviocytes and normal monocytes by in situ hybridization. Jlmmunol
  10. (1992). Angiogenesis inhibition suppresses collagen arthritis. JExp Med
  11. (1992). Anti-cytokine strategies. Eur Cytokine Network
  12. (1980). Anti-rheumatic drugs: present deadlock and vistas.
  13. (1991). Anti-tumor necrosis factor ameliorates joint disease in routine collagen-induced arthritis.
  14. (1990). Antibodies to soluble form of tumor necrosis factor (TNF) receptor have TNF-like activity.
  15. (1989). Arthritogenic actions of recombinant IL-1 and tumour necrosis factor alpha in the rabbit: evidence for synergistic interactions between cytokines in vivo. Clin Exp Immunol;
  16. (1985). Articular cartilage cultured with calabolin (pig interleukin-1) synthesized decreased number of normal proteoglycan molecules. BiochemJ
  17. (1978). Articular cartilage proteoglycans in aging and osteoarthritis. BiochemJ
  18. (1989). Beneficial effect of monoclonal antibody to interleukin receptors activated T cells rheumatoid arthritis. Ann Rheum Dis
  19. (1971). Biochemical and metabolic abnormalities in articular cartilage from osteo-arthritic human hips. II. Correlation of morphology with biochemical and metabolic data.
  20. (1993). Biological effects of the ethyl acetate extract of Tripterygium wtlfordii Hook F. Arthritis Rheum
  21. (1990). Biology of multifunctional cytokines:
  22. (1991). Blocking IL-I: interleukin receptor antagonist in vivo and in vitro. Immunol Today
  23. (1991). Catabolism of aggrecan in cartilage explants. Identification of major cleavage site within the interglobular domain.
  24. (1990). Cathepsin B and cysteine protease inhibitors in human osteoarthritis.
  25. (1992). Cell membranes barriers for antisense oligonucleotides. Antisense Res Dev
  26. (1986). Characteristics of bacterial lipopolysaccharide induction of interleukin-1 secretion by lipopolysaccharides. Clin Exp Immunol
  27. (1990). Characterization of TNF-alpha 254 Mediators of Inflammation Vol 3. 1994Cytokines andjoint conditions inhibitor. Evidence of immunological cross-reactivity with the TNF receptor.
  28. (1985). Chondrocyte-mediated depletion of articluar cartilage proteoglycans in vitro. BlochemJ
  29. (1994). Clinical efficacy of CP-66,248 [5-chloro-2,3-Mediators of Inflammation
  30. (1992). Clinical of biochemical markers of bone remodeling in osteoporosis. Bone
  31. (1983). Collagenase and collagenolytic activity in human osteoarthritic cartilage. Arthritis Rheum
  32. (1983). Collagenolytic activity and collagen matrix breakdown of the articular cartilage in the Pond-Nuki dog model of osteoarthritis. Arthritis Rheum
  33. (1982). Collagens act ligands to stimulate monocytes to produce mononuclear cell factor (MCF) and protaglandins (PGE2). Collagen Rel Res
  34. (1990). Comparison of the effect of interleukin 6 and interleukin collagenase and proteoglycan production by chondrocytes.
  35. (1986). Cysteine protease inhibitors of the cystatin super family. In: Barrett
  36. (1990). Cytokine production in the rheumatoid joint: implications for treatment. Ann Rheum Dis
  37. (1990). Cytokines and cytokine inhibitors antagonists in rheumatoid arthritis. Arthritis Rheum
  38. (1989). Cytokines in chronic inflammatory arthritis, II: Granulocyte-macrophage colony-stimulating factor in rheumatoid synovial effusions.
  39. (1994). Cytokines in models of arthritis. In:
  40. (1990). cytokines, and arthritis. Ann NYAcad Sci
  41. (1990). Detection of interleukin-8 biologic activity in synovial fluids from patients with rheumatoid arthritis and production of interleukin-8 mRNA by isolated synovial cells.
  42. (1990). Detection of transforming growth factor-beta in rheumatoid arthritis synovial tissue: lack of effect spontaneous cytokine production in joint cell cultures. ClinExpImmunol
  43. (1988). Dexamethasone inhibition of interleukin-1 beta production by human monocytes: posttranscriptional mechanisms.
  44. Dexamethasone-mediated inhibition of human T cell growth factor and gamma-interferon messenger RNA.
  45. (1987). Differential expression of Ia antigens by rheumatoid synovial lining cells.
  46. (1993). Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other steroidal antiinflammatory drugs.
  47. (1993). Dissociation of IL-lbeta synthesis and secretion in human blood monocytes stimulated with bacterial cell wall products.
  48. (1987). Down regulation of the receptors for tumor necrosis factor by
  49. (1989). Effect of interleukin-1 and tumour necrosis factor-alpha cartilage proteoglycan metabolism in vitro. Agents Actions
  50. (1988). Effect of neuropeptides production of inflammatory cytokines by human monocytes. Science
  51. (1983). Effect of nonsteroidal antiinflammatory drugs immune function. Semin Arthritis Rheum
  52. (1986). Effects of antimalarial drugs interleukin 1-induced cartilage proteoglycan degradation in vitro. JPharm Pharmacol
  53. (1993). Effects of oral administration of type II collagen rheumatoid arthritis. Science
  54. (1984). Effects of piroxicam mononuclear cells. Comparison with other antiarthritic drugs. Inflammation
  55. (1990). Elevated substance P and accelerated cartilage degradation in rabbit knees injected with interleukin-1 and tumor necrosis factor. Arthritis Rheum
  56. (1977). Endogenous activation of latent collagenase by rheumatoid synovial cells. NEnglJMed
  57. (1990). Endotoxin-responsive sequences control cachectin/ tumor necrosis factor biosynthesis at the translational level. JExpMed
  58. (1991). Enhanced production of neutrophilactivating peptide-interleukin-8 in rheumatoid arthritis.
  59. (1994). ETH 615, novel inhibitor of interleukin-8 (IL-8) production.
  60. (1993). Etiopathogenesis of osteoarthritis.
  61. (1988). Evaluation of CP-66,248 [5-chloro-2,3-dihydro-2-oxo-3-(2-theinylcarbonyl)-indole-l-carboxamide] in rheumatoid arthritis (RA). Arthritis Rheum
  62. (1989). Evidence for metalloproteinase and metalloproteinase inhibitor (TIMP) imbalance in human osteoarthritic cartilage.
  63. (1982). Evidence that extracellular cathepsin D is not responsible for the resorption of cartilage matrix in culture. Biochim Biophys Acta
  64. (1986). Evidence that interleukin-1 induction of synovial cell plasminogen activator is mediated by prostaglandin E2 and cyclic AMP. Arthritis Rheum
  65. (1992). Evolution of collagen arthritis in mice is arrested by treatment with antitumor necrosis factor (TNF) antibody recombinant soluble TNF receptor. Immunology
  66. (1988). Exacerbation of arthritis by IL-1 in rat joints previously injured by peptidoglycan-polysaccharide. Jlmmunol
  67. (1994). Excess of metalloprotease TIMP may contribute to cartilage degradation in osteoarthritis and rheumatoid arthritis. Lab Invest
  68. (1988). Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis.
  69. (1993). Expression of 92kD type IV collagenase/ gelatinase (gelatinase B) in osteoarthritis cartilage and its induction in normal human articular cartilage by interleukin-1.
  70. (1992). Expression of c-fos, c-jun, jun-b, metallothionein and metalloproteinase genes in human chondrocytes. FEBSLett
  71. (1991). Expression of metalloproteinases and metalloproteinase inhibitor in human arthritic synovium. Arthritis Rheum
  72. (1993). Expression of the cytokine RANTES in human rheumatoid synovial fibroblasts. Differential regulation of RANTES in human rheumatoid synovial fibroblasts. JBiol Chem
  73. (1990). Expression of the interleukin 6 gene in rheumatoid synovial fibroblasts. JRheumatol
  74. (1984). Extracellular presence of the lysomal proteinase cathepsin B in rheumatoid synovium and its activity at neutral pH. ArthritisRheum
  75. (1977). Further studies the activation of procollagenase, the latent precursor of bone collagenase. Effects of lysosomal cathepsin B, plasmin and kallikrein, and spontaneous activation.
  76. (1991). Gene expression (collagenase, tissue inhibitor of metalloproteinases, complement, and HLA-DR) in rheumatoid arthritis and osteoarthritis synovium. Arthritis Rheum
  77. (1993). genes and osteoarthritis.
  78. (1988). Genomic structure of the murine IL-6 gene: high degree conservation of potential regulatory sequences between and human. JImmunol
  79. (1987). Glucocorticoid regulation of lymphokine production by murine T lymphocytes. Lymphokine
  80. (1987). Glucocorticoids inhibit transcriptional and post-transcriptional expression of interleukin in U937 cells. Jlmmunol
  81. (1988). Glucocorticoids selectively inhibit the transcription of the interleukin beta gene and decrease the stability of interleukin beta mRNA.
  82. (1988). Glucocorticoids suppress the production of tumor necrosis factor alpha by lipopolysaccharide stimulated human monocytes. Immunology
  83. (1988). Heterogenous nature of the acute phase response. Differential regulation of human amyloid A, C-reactive protein, and other acute phase proteins by cytokines in Hep 3B cells. JImmunol
  84. (1993). Hormonal control of inflammatory responses. Mediators ofInflammation
  85. (1990). Human alveolar macrophage gene expression of interleukin-8 by tumor necrosis factor-alpha, lipopolysaccharide, and interleukin-1 beta. AmJ Respir Cell Mol Biol
  86. (1990). Human neutrophil collagenase. A distinct gene product with homology to other matrix metalloproteinases. JBiol Chem
  87. (1986). Human recombinant interleukin stimulates collagenase and prostaglandin E2 production by human synovial cells.
  88. (1987). Human recombinant interleukin-1 beta stimulates glycosaminoglycan production in human synovial fibroblast cultures. Arthritis Rheum
  89. (1988). Human recombinant interleukin-1 regulates cellular mRNA levels of dermatan sulphate proteoglycan protein. BiochemJ
  90. (1983). Hypothesizing about joints. In:
  91. (1975). Identification of immunoglobulins and complement in rheumatoid articular collagenous tissues. Arthritis Rheum
  92. (1990). IL-6 production by human articular chondrocytes. Modulation of its synthesis by cytokines, growth factors, and hormones in vitro. Jlmmunol
  93. (1988). Immunoassay, bioassay, and in situ hybridization of monokines in human arthritis. Progr Leucocyte Biol
  94. (1991). In situ hybridization studies of stromelysin and collagenase messenger RNA expression in rheumatoid synovium. Arthritis Rheum
  95. In vitro effect of select nonsteroidal antiinflammatory drugs the synthesis and activity of anabolic regulatory factors produced by osteoarthritic and rheumatoid synovial tissue.
  96. (1991). In vitro effects of IL-1 the synthesis of metalloprotease, TIMP, plasminogen activators and inhibitors in human articular cartilage.
  97. In vivo administration with IL-1 accelerates the development of collagen-induced arthritis in mice.
  98. (1987). Incidence of antibodies to native and denatured cartilage collagens (types II, IX and XI) and to type collagen in rheumatoid arthritis. Ann Rheum Dis
  99. (1990). Increased levels of soluble tumor necrosis factor receptors in the and synovial fluid of patients with rheumatic diseases. arthritis Rheum
  100. (1986). Induction of B2-interferon by tumor necrosis factor. A homeostatic mechanism in the control of cell proliferation. Cell
  101. (1988). Inhibition of monocyte IL-1 production by the anti-inflammatory compound SK&F 86002. IntJImmunopharmacol
  102. (1993). Inhibitory effects of bisbenzylisoquinolines synthesis of the inflammatory cytokines interleukin-1 and tumour necrosis factor-alpha. Mediators ofInflammation
  103. (1989). Interleukin (IL-6) and joint tissues. Ann NYAcad Sci
  104. (1990). Interleukin 6 enhances the production of tissue inhibitor of metalloproteinase (TIMP) but not that of matrix metalloproteinases by human fibroblasts.
  105. (1989). Interleukin 6: multifunctional cytokine regulating immune reactions and the acute phase protein response. Lab Invest
  106. (1988). Interleukin and tumor necrosis factor mRNA expression in rheumatoid arthritis: prolonged production of IL-lalpha. Clin Exp Immunol
  107. (1986). Interleukin induces leukocyte infiltration and cartilage proteoglycan degradation in the synovial joint.
  108. (1993). Interleukin type II receptor: decoy target for IL-1 that is regulated by interleukin 4. Science
  109. (1982). Interleukin-1 activity in the synovial fluid of patients with rheumatoid arthritis. Rheumatol Int
  110. (1990). Interleukin-1 preferentially stimulates the production of tissue-type plasminogen activator by human articular chondrocytes. Biochim Biophys Acta
  111. (1988). Interleukin-1 suppresses expression of cartilage-specific types II and IX collagens and increases types and III collagens in human chondrocytes. JClin Invest
  112. (1991). Interleukin-10 (ILl0) inhibits cytokine synthesis by human monocytes: autoregulatory role of ILl0 produced by monocytes. JExpMed
  113. (1990). Interleukin-6 and the acute phase response. BiochemJ
  114. (1991). Interleukin-6 induces the synthesis of tissue inhibitor of metalloproteinases-1/erythroid potentiating activity (TIMP1/EPA).
  115. (1991). Interleukin-6 localization in the synovial membrane in rheumatoid arthritis. Rheumatollnt
  116. (1994). Interleukin-I beta induces synthesis
  117. (1993). Intraarticular expression of biologically active interleukin 1-receptor-antagonist protein by vtvogene transfer.
  118. (1983). Isolation of interleukin like factor from human joint effusions. Arthritis Rheum
  119. (1992). IX207-887 in rheumatoid arthritis. A double-blind placebo-controlled study. Arthritis Rheum
  120. (1991). Localization of tumor necrosis factor alpha in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis. Arthritis Rheum
  121. (1992). Localization of tumor necrosis factor receptors in the synovial tissue and cartilage-pannus junction in patients with rheumatoid arthritis. Implications for local actions of tumor necrosis factor alpha. Arthritis Rheum
  122. (1991). Macrophage deactivation by interleukin-10. JExpMed
  123. (1988). Malemud cJ. Activation of neutral metalloprotease in human osteoarthritic knee cartilage: evidence for degradation in the protein of sulphated proteoglycan. Ann Rheum Dis
  124. (1993). Measuring circulating cytokines. JAppl Physiol
  125. (1993). Mechanisms of tissue destruction in rheumatoid arthritis.
  126. (1989). Mechanisms which take part in regulation of the response to tumor necrosis factor. Lymphokine Res
  127. (1992). Modification of proinflammatory cytokine production by the antirheumatic agents tenidap and naproxen. A possible correlate with clinical acute phase response. JImmunol
  128. (1987). Modulation by recombinant interleukin of synthesis of types and III collagens and associated procollagen mRNA levels in culture human cells. JBiol Chem
  129. (1990). Modulation of interleukin and tumor necrosis factor alpha of production of collagenase, tissue inhibitor of metalloproteinase and collagen types in differentiated and dedifferentiated articular chondrocytes. Biochim Biophys Acta
  130. (1990). Molecular cloning and expression of human 55 kDa tumor necrosis factor receptor. Cell
  131. (1989). Monokine-induced neutrophil chemotactic factor gene expression in human fibroblasts. JBiol Chem
  132. (1985). Mononuclear cell-conditioned medium containing mononuclear cell factor (MCF), homologous with interleukin 1, stimulates collagen and fibronectin synthesis by adherent rheumatoid synovial cells: effects of prostaglandin E and indomethacin. Coil Rel Res
  133. (1985). Morphologic and cytochemical changes in maturing and osteoarthritic articular cartilage in the temporomandibular joint of mice. Arthritis Rheum
  134. (1986). Neutral proteases in human osteoarthritic synovium. Arthritis Rheum
  135. (1990). Neutrophil chemotactic factor (IL-8) gene expression by cytokine-treated retinal pigment epithelial cells. AmJPathol
  136. (1987). Neutrophil chemotactic factor produced by lipopolysaccharide (LPS)-stimulated human blood mononuclear leukocytes: partial characterization and separation from interleukin (IL-1). Jlmmunol
  137. (1988). Neutrophil stimulation by recombinant cytokines and factor produced by IL-1 treated human synovial cell cultures. Immunology
  138. (1987). Osteoarthritis and related disorders.
  139. (1987). Osteoarthritis remodeling process.
  140. (1979). Participation of monocyte-macrophages and lymphocytes in the production of factor that stimulates collagenase and prostaglandin release by rheumatoid synovial cells.
  141. (1986). Pathogenesis of osteoarthritis. AmJMed
  142. (1989). Pattern of humoral reactivity to type II collagen in rheumatoid arthritis. Clin Exp Immunol
  143. (1984). Plasmin degradation of cartilage proteoglycan.
  144. (1991). plasminogen activators and inhibitor in human osteoarthritic cartilage. JRheumatol
  145. Presence of platelet glycoproteins Ib and IIb-IIIa in inflammatory and noninflammatory synovium.
  146. (1991). Prevention of human immunodeficiency virus type integrase expression in Escherichia coil by ribozyme.
  147. Production of monocyte chemoattractant protein-1 by inflamed synovial tissue and cultured synoviocytes.
  148. Properties of the novel proinflammatory supergene ’intercrine’ cytokine family. Ann Rev Immuno11991;
  149. (1991). Prospects for antisense nucleic acid therapy of and AIDS.
  150. (1993). Prostaglandin E differentially modulates cytokine secretion profiles of human T helper lymphocytes. Jlmmunol
  151. (1982). Prostaglandin E inhibits the production of human interleukin 2. JExp Med
  152. (1992). Protection against cartilage proteoglycan synthesis inhibition by antiinterleukin antibodies in experimental arthritis.
  153. (1983). Proteinase inhibitors of human articular cartilage. Collagen Rel Res
  154. (1991). Proteinase-mediated cartilage degradation in osteoarthritis. Sem Arthritis Rheum
  155. (1987). Proteoglycan-degrading acid metalloprotease activity in human osteoarthritic cartilage, and the effect of intraarticular steroid injections. Arthritis Rheum
  156. (1991). Purification and characterization of novel soluble receptor for interleukin-1. JExp Med
  157. (1990). Purification of soluble cytokine receptors from normal human urine by ligand affinity and immunoaffinity chromatography.
  158. (1993). purification, and characterization of novel immunosuppressive compounds from Triptergium. Arthritis Rheum
  159. (1990). Quantitative analysis of cytokine gene expression in rheumatoid arthritis. Jlmmunol
  160. (1991). Recombinant human interleukin-1 inhibits plasminogen activator inhibitor-1 (PAI-1) production by human articular cartilage and chondrocytes.
  161. Reduction of acute phase proteins with tenidap, cytokine-modulating antirheumatic drug. BrJRheum 1993; 3:a(suppl 3):
  162. (1992). Reduction of the severity of canine osteoarthritis by prophylactic treatment with oral doxycycline. Arthritis Rheum,
  163. (1990). Regulation of alloreactivity in vivo by soluble form of the interleukin-1 receptor. Science
  164. (1993). Regulation of human normal and osteoarthritic chondrocyte interleukin-1 receptor by antirheumatic drugs. Arthritis Rheum
  165. Regulation of IL-3 expression by glucocorticoids in cloned murine T lymphocytes.
  166. (1991). Regulation of interleukin-1 beta production by glucocorticoids in human monocytes: the mechanism of action depends the activation signal.
  167. (1990). required for the inhibition of proteoglycan synthesis by interleukin-1 in human articular cartilage. Arthritis Rheum
  168. (1993). Rheumatoid arthritis: etiology and pathogenesis.
  169. Rheumatoid arthritis: its present and future.
  170. (1990). Rheumatoid arthritis: pathophysiology and implications for therapy. NEnglJMed
  171. (1983). Serum amyloid-A protein concentration in rheumatoid arthritis and its role in monitoring disease activity. Ann Rheum Diseases
  172. (1988). Serum and synovial fluid levels of amyloid A protein and C-reactive protein in inflammatory and noninflammatory arthritis. JRheum
  173. (1989). Soluble cytokine receptors present in normal human urine. JExpMed
  174. (1980). Specific cleavage of human type III collagen by human polymorphonuclear leukocyte elastase. JBiol Chem
  175. (1990). Stimulation of human chondrocyte prostaglandin E production by recombinant human interleukin-1 and tumour necrosis factor. Biochim Biophys Acta
  176. (1985). Stimulation of procollagenase synthesis in human rheumatoid synovial fibroblasts by mononuclear cell factor/ interleukin 1. FEBSLett
  177. Stromelysin is activator of procollagenase. A study with natural and recombinant enzymes. BiochemJ 1987; 248: 265-268. 252 Mediators of Inflammation Vol 3. 1994Cytokines andjoint conditions
  178. (1991). Structural and functional studies the human hepatic IL-6-receptor: molecular cloning and overexpression in HepG2 cells.
  179. (1991). Subcutaneous IL-1 receptor antagonist in patients with rheumatoid arthritis. Arthritis Rheum
  180. (1987). Substance P activation of rheumatoid synoviocytes: neural pathway in pathogenesis of arthritis. Science
  181. (1993). Suramin induces deoligomerization of human tumor necrosis factor alpha.
  182. (1994). Synergism of interleukin and interleukin 6 induces amyloid A (SAA) production while depressing fibrinogen: quantitative analysis. JRheum
  183. (1991). Synovial brane histology and immunopathology in rheumatoid arthritis and osteoarthritis. Arthritis Rheum
  184. (1975). Synovial membrane and fluid morphologic alterations in early rheumatoid arthritis: microvascular injury and virus-like particles. AnnNYAcadSci
  185. (1991). Synovial tissue macrophage of the chemotactic cytokine IL-8. Jlmmunol
  186. (1990). Synthetic analogues of fumagilin that inhibit angiogenesis and suppress tumour growth. Nature
  187. (1993). Tethering ribozymes to retroviral packaging signal for destruction of viral RNA.
  188. (1992). Tetracyclines suppress matrix metalloproteinase activity in adjuvant arthritis and in combination with flurbiprofen, ameliorate bone damage. JRheumatol
  189. (1986). The action of human articular cartilage metalloprotease proteoglycan and link protein. Similarities between products of degradation in sltu and in vitro. Biochem
  190. (1972). The assessment of rheumatoid arthritis: study based measurements of acute phase reactants. QuartJMed
  191. (1989). The biology of osteoarthritis. NEnglJMed
  192. (1994). The clinical value of C-reactive protein (CRP) measurement in the management of rheumatoid arthritis. Seminars Arthritis Rheum
  193. (1973). The effects of antiinflammatory drugs the acute-phase proteins in rheumatoid arthritis.
  194. (1992). The IL-6 signal transducer, gpl30: oncostatin M receptor and affinity converter for the LIF receptor. Science
  195. (1989). The molecular biology of interleukin and the acute phase response. In:
  196. (1992). The prostaglandin E analogue, misoprostol, regulates inflammatory cytokines and immune functions
  197. (1974). The reaction of articular cartilage to injury and osteoarthritis.
  198. (1989). The regulation of interferon production by aspirin and other inhibitors of the cyclooxygenase pathway and agents influencing calcium channel flux. Bull NYAcad Med
  199. (1988). The relation of radiographic changes to acute-phase proteins and rheumatoid factor in 200 patients with rheumatoid arthritis. ScandJRheum
  200. (1992). The susceptibility sequence to rheumatoid arthritis is cross-reactive B cell epitope shared by the Escherichia coli heat shock protein dnaj and the histocompatibility leukocyte antigen DRB 10401 molecule.
  201. (1988). The transcription of the interleukin beta gene is induced with PMA and inhibited with dexamethasone in U937 cells.
  202. (1993). tissue inhibitor, and proteoglycan fragments in knee synovial fluid in human osteoarthritis. Arthritis Rheum
  203. (1991). TNF signal transduction and TNF-responsive genes. In: TumorNecrosis Factor. Structure, Function andMechanism ofAction.
  204. (1992). Transcriptional and post-transcriptional regulation of interleukin gene expression. IntJImmunopharm
  205. (1990). Transcriptional factors that regulate human IL-1/hemopoietin gene expression. Hematopoesis
  206. (1990). Transforming growth factor beta is potent inhibitor of interleukin-1 (IL-1) receptor expression: proposed mechanism of inhibition of IL-1 action. JExp Med
  207. (1991). Transgenic mice expressing human tumour necrosis factor: predictive genetic model of arthritis.
  208. (1992). Transition from interleukin lbeta (IL-lbeta) to IL-lalpha production during maturation of inflammatory macrophages in vivo. JExp Med
  209. (1993). Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum
  210. (1991). Tumor necrosis factor in inflammation: relation to other mediators and to macrophage antitumour defence. Pharmacological Research
  211. Tumor necrosis factor, its receptors and the connection with imerleukin and interleukin
  212. (1991). Tumor necrosis factor. New insights into the molecular mechanisms of its multiple actions.
  213. (1987). Tumor necrosis factors--TNF alpha and TNF beta: their structure and pleiotropic biological effects.
  214. (1988). Tumor necrosis, cachexia, shock and chronic inflammation. Ann Rev Biochem
  215. (1986). Tumour necrosis factor alpha stimulates resorption and inhibits synthesis of proteoglycan in cartilage. Nature
  216. (1990). Two tumor necrosis factor-binding proteins purified from human urine. Evidence for immunological reactivity with cell surface tumor necrosis factor receptors. JBiol Chem
  217. (1986). Type IX collagen is potent inducer of PGE2 and interleukin production by human macrophages.
  218. (1993). Up-regulation by tumor necrosis factor of intercellular adhesion molecule expression and function in synovial fibroblasts and its inhibition by glucocorticoids. Arthritis Rheum
  219. (1986). Workshop etiopathogenesis of osteoarthritis: proceedings and recommendations.